Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …

Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …

Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …

Survival and treatment options are limited for patients with brain metastases arising from non-
small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments …

Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …

Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …